A5060465607- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Lipid metabolism and disorders
- Pharmaceutical Economics and Policy
- Blood properties and coagulation
- Antiplatelet Therapy and Cardiovascular Diseases
- Adipokines, Inflammation, and Metabolic Diseases
- Atherosclerosis and Cardiovascular Diseases
- Diabetes Treatment and Management
- HIV-related health complications and treatments
- Pharmaceutical Practices and Patient Outcomes
- Cardiovascular Function and Risk Factors
- Liver Disease Diagnosis and Treatment
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- COVID-19 Clinical Research Studies
- Cerebrovascular and Carotid Artery Diseases
- Blood Pressure and Hypertension Studies
- Cardiovascular Health and Risk Factors
- Protease and Inhibitor Mechanisms
- Protein Kinase Regulation and GTPase Signaling
- Cardiac Health and Mental Health
Icahn School of Medicine at Mount Sinai
2016-2025
Cardiovascular Institute of the South
2014-2024
Mount Sinai Medical Center
2013-2024
Mount Sinai Hospital
2010-2024
Arrowhead Pharmaceuticals (United States)
2024
Royal Adelaide Hospital
2014-2024
Mount Sinai Hospital
2018-2024
Mount Sinai Hospital
2017-2024
Monash University
2024
University of Michigan
1998-2023
Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused markedly elevated levels of low-density lipoprotein (LDL) cholesterol. This disorder associated with genetic variants that result in virtually absent (null–null) or impaired (non-null) LDL-receptor activity. Loss-of-function the gene encoding angiopoietin-like 3 (ANGPTL3) are hypolipidemia and protection against atherosclerotic disease. Evinacumab, a monoclonal antibody ANGPTL3, has shown...
<h3>Background</h3> Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol small, dense low-density particles; and free fatty acid levels. Niacin reduces concentrations of triglyceride-rich small particles while increasing It also lowers levels acids lipoprotein(a). However, the use niacin in patients with diabetes has been discouraged because doses can worsen glycemic control. We evaluated efficacy safety once-daily extended-release (ER)...
BACKGROUND A growing body of evidence from epidemiological data, animal studies, and clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin-treated, high-risk patients. For more than 3 decades, cholesterol has been employed principal measure associated with low HDL-cholesterol concentrations. The physicochemical functional heterogeneity present important challenges investigators field who are seeking identify effective laboratory methods develop a...
Background— Nuclear magnetic resonance (NMR) spectroscopy measures the number and size of lipoprotein particles instead their cholesterol or triglyceride content, but its clinical utility is uncertain. Methods Results— Baseline lipoproteins were measured by NMR in 27 673 initially healthy women followed up for incident cardiovascular disease (n=1015) over an 11-year period. After adjustment nonlipid risk factors, hazard ratios 95% confidence intervals top versus bottom quintile NMR-measured...
Abstract. There is abundant evidence that the risk of atherosclerotic vascular disease directly related to plasma cholesterol levels. Accordingly, all national and transnational screening therapeutic guidelines are based on total or LDL cholesterol. This presumes most important lipoprotein‐related proatherogenic variable. On contrary, appears be more number circulating atherogenic particles contact enter arterial wall than measured concentration in these lipoprotein fractions. Each contains...
Muscle-related statin intolerance is reported by 5% to 20% of patients.To identify patients with muscle symptoms confirmed rechallenge and compare lipid-lowering efficacy for 2 nonstatin therapies, ezetimibe evolocumab.Two-stage randomized clinical trial including 511 adult uncontrolled low-density lipoprotein cholesterol (LDL-C) levels history or more statins enrolled in 2013 2014 globally. Phase A used a 24-week crossover procedure atorvastatin placebo having only but not placebo. In phase...
This document has been developed as an Expert Consensus Document (ECD) by the American College of Cardiology Foundation (ACCF), Association for Clinical Chemistry (AACC), Chest Physicians (ACCP), Emergency (ACEP),
<h3>Importance</h3> Secretory phospholipase A<sub>2</sub>(sPLA<sub>2</sub>) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA<sub>2</sub>inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect cardiovascular outcomes is unknown. <h3>Objective</h3> To determine the of sPLA<sub>2</sub>inhibition with outcomes. <h3>Design, Setting, Participants</h3> A double-blind, randomized, multicenter trial at 362 academic community...
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment lipid-lowering therapies at maximum tolerated doses, an increased risk of atherosclerosis. In such patients, the efficacy and safety subcutaneous intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known.In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients or without heterozygous familial...
Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when added background lipid-lowering therapy.The safety of alirocumab was evaluated in patients with at least 2 consecutive LDL-C values <25 or <15 mg/dl the ODYSSEY program, follow-up as long 104 weeks.Pooled data from 14 trials were analyzed (double-blind treatment 8 weeks; n = 3,340 alirocumab, 1,894 control [placebo ezetimibe]; representing 4,029...